Biological
AD17002
AD17002 is a biological therapy with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
3
75%
Ph phase_2
1
25%
Phase Distribution
3
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 2Efficacy & side effects
1(25.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(3)
Detailed Status
Completed3
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 13 (75.0%)
Phase 21 (25.0%)
Trials by Status
not_yet_recruiting125%
completed375%
Recent Activity
0 active trials
Showing 4 of 4
not_yet_recruitingphase_2
A Multi-dose Study on the Safety and Efficacy of Self-administered Intranasal AD17002 Treatment for Eosinophilic Asthma
NCT07250594
completedphase_1
Tolerability and Potential Efficacy of AD17002 in Subjects With Allergic Rhinitis
NCT04088721
completedphase_1
AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma
NCT05985694
completedphase_1
Evaluating Safety, Tolerability, and Potential Efficacy of Intranasal AD17002 in Adults With Mild to Moderate COVID-19
NCT05069610
Clinical Trials (4)
Showing 4 of 4 trials
NCT07250594Phase 2
A Multi-dose Study on the Safety and Efficacy of Self-administered Intranasal AD17002 Treatment for Eosinophilic Asthma
NCT04088721Phase 1
Tolerability and Potential Efficacy of AD17002 in Subjects With Allergic Rhinitis
NCT05985694Phase 1
AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma
NCT05069610Phase 1
Evaluating Safety, Tolerability, and Potential Efficacy of Intranasal AD17002 in Adults With Mild to Moderate COVID-19
All 4 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 4